Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC38	Pictilisib	1	72	sigmoid	sigmoid	HCC38 pictilisib 0 1 72	8	1.759	7.16	0.562	0.125	1.04	0.377	0.725	0.992	5.12e-07	NA	Inf	0.647	0.896	0.797	0.529	0.742	0.992	5.77e-07	NA
HCC38	Everolimus	3	72	sigmoid	sigmoid	HCC38 everolimus 0 3 72	8	1.437	5.11	0.511	0.429	0.000567	0.299	0.1	0.934	0.000284	NA	573000000.0	0.668	0.707	0.000349	0.53	0.1	0.932	0.000308	NA
HCC70	AZD8055	2	72	sigmoid	sigmoid	HCC70 AZD8055 0 2 72	8	1.724	0.17	0.404	0.346	0.0331	0.385	0.897	0.996	7.36e-08	NA	Inf	0.543	0.728	0.0284	0.531	0.905	0.996	6.22e-08	NA
HCC70	Trametinib	3	72	sigmoid	sigmoid	HCC70 trametinib 0 3 72	8	2.463	Inf	0.56	0.361	0.00419	0.548	0.954	0.95	0.000123	NA	Inf	0.542	0.618	0.00342	0.533	0.965	0.958	7.33e-05	NA
BT-20	Trametinib	1	72	sigmoid	sigmoid	BT20 trametinib 0 1 72	8	2.016	14.3	0.54	0.225	0.135	0.458	0.534	0.989	1.3e-06	NA	Inf	0.59	0.791	0.0955	0.534	0.545	0.989	1.43e-06	NA
HCC70	TGX221	1	72	sigmoid	sigmoid	HCC70 TGX-221 0 1 72	8	1.381	0.539	0.344	0.244	0.245	0.278	1.03	0.986	2.58e-06	NA	Inf	0.578	0.84	0.229	0.536	1.02	0.986	2.87e-06	NA
BT-20	MK2206	1	72	sigmoid	sigmoid	BT20 MK-2206 0 1 72	8	2.089	Inf	0.732	0.102	4.16	0.529	0.345	0.671	0.0357	NA	Inf	0.741	0.898	4.14	0.538	0.337	0.676	0.034	NA
HCC70	AZD8055	1	72	sigmoid	sigmoid	HCC70 AZD8055 0 1 72	8	1.339	0.0485	0.242	0.442	0.0243	0.26	1.06	0.976	1.32e-05	NA	Inf	0.529	0.721	0.0222	0.54	1.08	0.974	1.81e-05	NA
HCC70	Sirolimus	1	72	sigmoid	sigmoid	HCC70 rapamycin 0 1 72	8	1.416	37.6	0.533	0.397	0.00426	0.298	0.1	0.742	0.0172	NA	125000000.0	0.687	0.732	0.00186	0.541	0.1	0.74	0.0175	NA
HCC70	AS605240	3	72	sigmoid	sigmoid	HCC70 AS-605240 0 3 72	8	2.447	Inf	0.58	0.112	0.427	0.549	1.18	0.985	3.24e-06	NA	Inf	0.562	0.877	0.345	0.544	1.24	0.982	6.14e-06	NA
HCC1806	ZSTK474	3	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 3 72	8	3.162	Inf	0.654	0.0322	1.18	0.65	4.68	0.99	1.03e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC38	PIK-93	2	72	sigmoid	sigmoid	HCC38 PIK-93 0 2 72	8	2.107	31.9	0.661	0.0151	2.16	0.497	1.86	0.922	0.000468	NA	Inf	0.676	0.987	1.97	0.545	1.87	0.907	0.000813	NA
HCC1806	ZSTK474	1	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 1 72	8	2.709	Inf	0.602	0.037	1.17	0.599	4.88	0.99	1.12e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC1806	ZSTK474	2	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 2 72	8	2.794	Inf	0.613	0.036	1.16	0.61	5.0	0.99	1.1e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
BT-20	Everolimus	2	72	flat	flat	BT20 everolimus 0 2 72	8	1.785	Inf	0.426	0.574	0.0	0.426	0.01	NA	NA	0.426	Inf	0.547	0.547	0.0	0.547	0.01	NA	NA	0.547
Hs 578T	Alpelisib	3		sigmoid	sigmoid	Hs578T alpelisib 3	8	2.856	Inf	0.712	0.0759	0.872	0.616	0.828	0.963	5.21e-05	NA	Inf	0.641	0.901	0.65	0.553	0.853	0.955	8.85e-05	NA
HCC70	AZD8055	3	72	sigmoid	sigmoid	HCC70 AZD8055 0 3 72	8	2.442	Inf	0.571	0.287	0.0133	0.574	1.17	0.98	8.55e-06	NA	Inf	0.554	0.694	0.0116	0.556	1.17	0.974	1.69e-05	NA
HCC70	Trametinib	1	72	sigmoid	sigmoid	HCC70 trametinib 0 1 72	8	1.421	0.015	0.339	0.521	0.00411	0.34	0.879	0.966	4.1e-05	NA	Inf	0.566	0.653	0.00373	0.566	0.875	0.968	3.23e-05	NA
HCC38	Sirolimus	3	72	sigmoid	sigmoid	HCC38 rapamycin 0 3 72	8	1.420	86.3	0.535	0.403	0.000236	0.361	0.1	0.901	0.000982	NA	75575.0	0.687	0.727	0.000198	0.569	0.1	0.889	0.00136	NA
HCC70	WYE-125132	1	72	sigmoid	sigmoid	HCC70 WYE-132 0 1 72	8	1.382	0.0518	0.346	0.418	0.0175	0.348	1.1	0.985	3.58e-06	NA	Inf	0.579	0.727	0.0165	0.579	1.09	0.983	4.63e-06	NA
HCC70	Sirolimus	3	72	sigmoid	sigmoid	HCC70 rapamycin 0 3 72	8	2.548	310.0	0.732	0.227	0.000433	0.63	0.1	0.676	0.034	NA	22876.0	0.693	0.736	0.000237	0.58	0.1	0.659	0.0397	NA
BT-549	Sirolimus	3	72	flat	flat	BT549 rapamycin 0 3 72	8	1.703	Inf	0.455	0.482	0.0	0.455	0.01	0.376	0.243	0.518	Inf	0.582	0.626	0.0	0.582	0.01	0.436	0.179	0.625
HCC70	Trametinib	2	72	sigmoid	sigmoid	HCC70 trametinib 0 2 72	8	1.721	0.506	0.504	0.395	0.00469	0.467	0.581	0.944	0.000179	NA	Inf	0.612	0.687	0.00389	0.585	0.57	0.948	0.000138	NA
HCC38	PIK-93	3	72	sigmoid	sigmoid	HCC38 PIK-93 0 3 72	8	1.382	5.05	0.598	0.061	2.34	0.358	1.63	0.919	0.000533	NA	Inf	0.734	0.959	2.23	0.586	1.64	0.914	0.000645	NA
HCC70	WYE-125132	3	72	sigmoid	sigmoid	HCC70 WYE-132 0 3 72	8	2.417	Inf	0.592	0.246	0.0209	0.606	1.64	0.995	1.48e-07	NA	Inf	0.576	0.739	0.019	0.588	1.64	0.996	7.52e-08	NA

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)